Market Overview

Spinal Muscular Atrophy (SMA): Pipeline Insights, 2018 - Roche, Cytokinetics, Astellas, Avexis, Novartis, Genzyme and AurieMed -


The "Spinal
Muscular Atrophy (SMA) - Pipeline Insight, 2018"
drug pipelines
has been added to's offering.

This report offers a comprehensive insight of the pipeline (under
development) therapeutics scenario and growth prospects across Spinal
Muscular Atrophy (SMA) development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

The report assesses the active Spinal Muscular Atrophy (SMA) pipeline
products by developmental stage, product type, molecule type, and
administration route.


  • The report provides a snapshot of the pipeline development for the
    Spinal Muscular Atrophy (SMA)
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    the Spinal Muscular Atrophy (SMA)
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Spinal Muscular Atrophy (SMA)
  • The report also covers the dormant and discontinued pipeline projects
    related to the Spinal Muscular Atrophy (SMA)

Companies Features

  • Roche
  • Cytokinetics
  • Astellas
  • Avexis
  • Novartis
  • Genzyme
  • AurieMed

Key Topics Covered

1. Report Introduction

2. Spinal Muscular Atrophy (SMA) Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit

View Comments and Join the Discussion!